Assessing feasibility of targeted primary care referrals for patients with clinical suspicion of interstitial lung disease using lung ultrasound: a prospective case finding study. The potential benefits of LUS utilization.
Journal
Sarcoidosis, vasculitis, and diffuse lung diseases : official journal of WASOG
ISSN: 2532-179X
Titre abrégé: Sarcoidosis Vasc Diffuse Lung Dis
Pays: Italy
ID NLM: 9610928
Informations de publication
Date de publication:
29 Jun 2023
29 Jun 2023
Historique:
received:
02
12
2022
accepted:
08
06
2023
medline:
29
6
2023
pubmed:
29
6
2023
entrez:
29
6
2023
Statut:
epublish
Résumé
In Primary Health Care (PHC) many interstitial lung disease (ILD) cases may remain at diagnostic delay, due to their challenging presentation and the limited experience of general practitioners (GPs) in recognizing their early symptoms. We have designed a feasibility study to investigate early ILD case-finding competency between PHC and tertiary care. A cross-sectional prospective case-finding study was launched at two private health care centers of Heraklion, Crete, Greece, during nine months (2021-2022). After clinical assessment by GP, PHC attenders, who agreed to participate in the study, were referred to the Respiratory Medicine Department, University Hospital of Heraklion, Crete, underwent Lung Ultrasound (LUS) and those with an overall suspicion for ILDs underwent high resolution computed tomography (HRCT) scan. Descriptive statistics and chi-square tests were used. Multiple Poisson regression analysis was performed to explain positive LUS and HRCT decision with selected variables. One hundred and nine patients out of 183 were finally included (54.1% females; mean age 61, SD: 8.3 years). Thirty-five (32.1%) were current smokers. Overall, two out of ten cases were assessed to need HRCT due to a moderate or high suspicion (19.3%; 95%CI 12.7, 27.4). However, in those who had dyspnea in relation to counterparts, a significantly higher percentage of patients with LUS findings (57.9% vs. 34.0%, p=0.013) was found, as in those who had crackles (100.0% vs. 44.2%, p= 0.005). Detected possible ILD provisional labelling cases were 6, and most importantly, 5 of those cases were considered highly suspicious for further evaluation based on LUS findings. This is a feasibility study exploring potentials by combining data of medical history, basic auscultation skills, as crackles detection, and inexpensive and radiation-free imaging technique, such as LUS. Cases of ILD labeling may be hidden within PHC, sometimes, much before any clinical manifestation.
Sections du résumé
BACKGROUND
BACKGROUND
In Primary Health Care (PHC) many interstitial lung disease (ILD) cases may remain at diagnostic delay, due to their challenging presentation and the limited experience of general practitioners (GPs) in recognizing their early symptoms.
OBJECTIVE
OBJECTIVE
We have designed a feasibility study to investigate early ILD case-finding competency between PHC and tertiary care.
METHODS
METHODS
A cross-sectional prospective case-finding study was launched at two private health care centers of Heraklion, Crete, Greece, during nine months (2021-2022). After clinical assessment by GP, PHC attenders, who agreed to participate in the study, were referred to the Respiratory Medicine Department, University Hospital of Heraklion, Crete, underwent Lung Ultrasound (LUS) and those with an overall suspicion for ILDs underwent high resolution computed tomography (HRCT) scan. Descriptive statistics and chi-square tests were used. Multiple Poisson regression analysis was performed to explain positive LUS and HRCT decision with selected variables.
RESULTS
RESULTS
One hundred and nine patients out of 183 were finally included (54.1% females; mean age 61, SD: 8.3 years). Thirty-five (32.1%) were current smokers. Overall, two out of ten cases were assessed to need HRCT due to a moderate or high suspicion (19.3%; 95%CI 12.7, 27.4). However, in those who had dyspnea in relation to counterparts, a significantly higher percentage of patients with LUS findings (57.9% vs. 34.0%, p=0.013) was found, as in those who had crackles (100.0% vs. 44.2%, p= 0.005). Detected possible ILD provisional labelling cases were 6, and most importantly, 5 of those cases were considered highly suspicious for further evaluation based on LUS findings.
CONCLUSIONS
CONCLUSIONS
This is a feasibility study exploring potentials by combining data of medical history, basic auscultation skills, as crackles detection, and inexpensive and radiation-free imaging technique, such as LUS. Cases of ILD labeling may be hidden within PHC, sometimes, much before any clinical manifestation.
Identifiants
pubmed: 37382071
doi: 10.36141/svdld.v40i2.14017
pmc: PMC10494744
doi:
Types de publication
Journal Article
Langues
eng
Pagination
e2023022Références
Intensive Care Med. 2012 Apr;38(4):577-91
pubmed: 22392031
Chest. 2021 Sep;160(3):983-993
pubmed: 33905677
Sarcoidosis Vasc Diffuse Lung Dis. 2015 Aug 03;32 Suppl 1:28-35
pubmed: 26237442
Am J Respir Crit Care Med. 2006 Oct 1;174(7):810-6
pubmed: 16809633
NPJ Prim Care Respir Med. 2014 Sep 11;24:14054
pubmed: 25208940
Eur Respir J. 2013 May;41(5):1207-18
pubmed: 23100500
Diagnostics (Basel). 2020 Aug 16;10(8):
pubmed: 32824302
J Ultrasound Med. 2018 Mar;37(3):689-696
pubmed: 28877354
Heart Vessels. 2021 Aug;36(8):1151-1158
pubmed: 33486554
Core Evid. 2016 Jul 01;11:11-22
pubmed: 27445644
ESC Heart Fail. 2020 Oct;7(5):2941-2947
pubmed: 32697034
Front Med (Lausanne). 2021 Nov 04;8:751181
pubmed: 34805219
J Clin Med. 2021 Aug 06;10(16):
pubmed: 34441772
BMJ Open Respir Res. 2021 Jul;8(1):
pubmed: 34233892
J Ultrasound Med. 2016 Oct;35(10):2075-86
pubmed: 27503755
Front Med (Lausanne). 2022 Jun 09;9:861076
pubmed: 35755040
Prim Care Respir J. 2011 Jun;20(2):190-8, 2 p following 198
pubmed: 21597667
Eur Respir Rev. 2017 Jan 3;26(143):
pubmed: 28049126
Arch Rheumatol. 2020 Jun 25;36(1):19-25
pubmed: 34046565
Int J Environ Res Public Health. 2011 Aug;8(8):3287-98
pubmed: 21909307
Respiration. 2017;93(1):15-22
pubmed: 27880957
J Health Soc Behav. 1983 Dec;24(4):385-96
pubmed: 6668417
Ann Am Thorac Soc. 2019 Mar;16(3):393-396
pubmed: 30620617
Am J Respir Crit Care Med. 2022 Aug 1;206(3):247-259
pubmed: 35353660
BMC Pulm Med. 2018 Jun 18;18(1):103
pubmed: 29914454
Am J Respir Crit Care Med. 2011 Feb 15;183(4):431-40
pubmed: 20935110
Cardiovasc Ultrasound. 2014 Jul 04;12:25
pubmed: 24993976
J Ultrasound Med. 2017 Dec;36(12):2525-2532
pubmed: 28656715
Sarcoidosis Vasc Diffuse Lung Dis. 2021;38(3):e2021031
pubmed: 34744425
Eur Respir J. 2022 Jul 13;60(1):
pubmed: 34949706
Respir Res. 2021 Jun 8;22(1):175
pubmed: 34103046
Respir Med. 2021 Aug-Sep;185:106490
pubmed: 34130097
Lancet. 2015 Jan 10;385(9963):117-71
pubmed: 25530442
Am J Respir Crit Care Med. 2022 May 1;205(9):e18-e47
pubmed: 35486072
Chest. 2021 Jan;159(1):128-137
pubmed: 32805240
Lancet Respir Med. 2014 Jan;2(1):e1
pubmed: 24461905
Am J Respir Crit Care Med. 2019 Nov 1;200(9):1146-1153
pubmed: 31241357
Am J Respir Crit Care Med. 2011 Oct 1;184(7):842-7
pubmed: 21719755
Eur Respir Rev. 2014 Mar 1;23(131):40-54
pubmed: 24591661
Ultrasound J. 2021 Jun 30;13(1):34
pubmed: 34191145
Eur Respir J. 2015 Sep;46(3):795-806
pubmed: 25976683
ERJ Open Res. 2020 Jan 27;6(1):
pubmed: 32010718
Semin Respir Crit Care Med. 2022 Dec;43(6):764-779
pubmed: 36307108
BMC Pulm Med. 2018 Jan 17;18(1):9
pubmed: 29343236
Clin Interv Aging. 2018 Mar 22;13:437-449
pubmed: 29606857
Ultrasound J. 2019 Nov 19;11(1):31
pubmed: 31749019